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Oral Presentations S189Methods: A retrospective review of the medical records of alloge-
neic and autologous HSCT recipients transplanted at Memorial
Sloan Kettering Cancer Center between January 1997 and Decem-
ber 2006 was performed. A history of CAD included$ 1 of the fol-
lowing: coronary revascularization (PCI), coronary artery bypass
grafting surgery (CABG), obstructive CAD by catheterization
(.50% stenosis), ischemia by stress testing or documented history
of myocardial infarction (MI).
Results: Results are summarized in the table. 715 patients, age
40 years or older, who underwent 750 HSCTs were identified.
67% received autologous and 33% allogeneic HSCT. 46 pa-
tients who underwent 48 transplants were confirmed to have
CAD: 41% had a history of MI, 48% PCI, 24% CABG and
11% a positive stress test alone. Patients with CAD were
more often males who were older at transplant. Diabetes and
hypercholesterolemia were more prevalent in the CAD group.
Smoking history and hypertension were not significantly differ-
ent. There was no difference in cancer type or in protocol.
All-cause death during transplantation and death at one year
were the same, as was urgent admission to the ICU. The aver-
age length of stay was significantly longer in the control group
than in the CAD group, due to outliers in the control group.
Cardiac complications, including arrhythmias, myocardial infarc-
tion and new cardiomyopathy, were uncommon and did not oc-
cur more frequently in the CAD group than in the control
group.
Conclusions: This study demonstrates that patients with concur-
rent CAD can be safely transplanted, even with ablative regimens.
Pre-transplantation screening likely imposes a selection bias for pa-
tients with less severe CAD.
Characteristics and outcomes for CAD patients vs. controls
CAD (%) Control (%) p-valueNumber of Patients 46 669
Autologous/Allogeneic 36 (75) /
12 (25)
470 (67) /
232 (33)0.27Ablative/Nonablative 45 (94) /
3 (6)641 (91) /
61 (9)0.79Male 40 (83) 410 (58) 0.001*
Age at transplant ±
SE in yrs61.756 0.91 55.056 0.31 \0.001*Diabetes mellitus 7 (22) 44 (7) 0.038*
Hypercholesterolemia 22 (48) 132 (20) \0.001*
Smoking 23 (50) 275 (41) 0.279
Hypertension 14 (30) 185 (28) 0.734
Death during
transplant1 (2) 42 (6) 0.514Deaths at 1yr 8 (17) 130 (19) 0.849
ICU admission 6 (13) 68 (10) 0.460
Cardiac events 5 (11) 32 (5) 0.080
Length of hospital
stay in days24.176 1.35 29.506 0.79 0.001**p\0.05, p-value calculated for continuous variables using the t-Test
and for categorical variables using the Fisher’s Exact test.CRA – DATA MANAGEMENT ORAL
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Background: Laboratory ‘‘events’’ go by different names, such as
Error, Accident, Incident, Occurrence or Deviation to name a few.
Reporting of events in the hospital setting is generally well defined
but those occurring in CPF are as yet not classified, though some
of these are mandatory FDA-reportable.
FACT Standards offer definitions for four events: Biological
Product Deviation (BPD) relates to product contamination; Er-
rors and Accidents relate to product safety, purity and potency;
Variance refers to planned deviation from operating procedure;
and Adverse Event refers to any event related to an interven-
tion.
FDA on the other hand has only one broad concern: Prevention
of introduction, transmission, and spread of communicable dis-
ease through a distributed HCT/P; resulting in HCT/P deviation
or an Adverse Reaction (and both are listed together under
Complaint).
However in the CPF daily routine, we come across a number of
events which are not covered by FACTor FDA regulatory standards,
but which must be addressed if our goal is to improve the quality,
efficiency and safety of the laboratory, its patient, product and
personnel.
Thus far no work has been published referring to events in the
CPF. We at NMH are defining a system for Event Management
which may be worth looking at.
Event Classification: See Table 1.
Discussion: Published data on errors occurring hospital-wide
concur that, Errors are much more frequent than reported Ad-
verse Events (and may be as many as 100:1)1,2; At most times,
Management is unaware of the magnitude of the problem2;
Event-reporting systems may be able to produce valuable
information1,2; Humans are fallible and errors are to be ex-
pected3,4,5; and Errors result from system failures, not people
failures2,3, and 5.
In all likelihood CPF has many events which go unidentified and
unreported in the absence of a standardized system for documenting
events1,2. Further, events go unreported out of fear of embarrass-
ment, punishment or litigation6 or of reprisal, loss of reputation,
job or extra work7 and from lack of belief that reporting will lead
to improvement8.
Conclusion:When CPF events are documented accurately and em-
ployees assured of no punitive action, it may be possible to analyze
and trend events to their source; and implement corrective and
preventive measures to help reduce them over time, leading to over-




1.1 BPD: (Distributed, Contaminated,
Recall, Adverse Reaction etc)
1.2 Improper Product Release
(UMN, Without Review or
Signature etc)1.3 Product Label related
1.4 Product Bag related
1.5 Patient-Donor Information
related
1.6 Other: (Improper Processing,
Storage etc)
2. SOP Deviation:
2.1 Not Per Procedure, or No Procedure
2.2 Wrong Procedure or Form
2.3 In-process Label related:2.3 A Wrong or No Label
2.3 B Wrong, No or Incomplete2.4 Data Related:
2.4 A Wrongor No Data or Calculation
2.4 B No or Poor Verification(Continued )
S190 Oral Presentations(Continued )2.4 C No or Poor Primary or
Secondary Review2.4 D Poor Data Correction
2.4 E Other Data related2.5 Poor Notification (Physician,
Tech, Participating Program,
Vendor etc)2.6 Other (Missed Review, No Review,
Inappropriate Release of
PHI, Data etc)3. Planned Deviation:
3.1 HCT/P Related:3.1 A Non-Conforming Product, as
Received3.1 B Non-Conforming to CPF Release
Criteria3.1 C Other
3.2 SOP related
4. Equipment or Supply related:
4.1 Recall or Notice
4.2 Calibration, Qualification or
Maintenance related
4.3 Alarm or Monitor System related
4.4 Other (Expired Lot, Out of Order or







DEVELOPMENT OF A DISTRIBUTED RESEARCH DATA MANAGEMENT
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The role of a reliable data management and information system in
oncology services is well established. In addition to well-known risk
determining factors, the outcome of treatment efforts is also influ-
enced by the geography and genetic makeup of the population being
treated. The toxicity of the therapy used requires closemonitoring of
protocol outcomes to determine the risk benefit. Also advances in di-
agnostic tools and criteria, and identification of new risk factors re-
quire constant update of the data items being collected in such
a system.
Commercially available oncology data management and infor-
mation processing systems are not always useful in fulfilling
these requirements. The initial and maintenance costs for these
programs also make it less feasible for use in resource poor
countries.
Here we report our experience in the successful development
and implementation of a comprehensive, efficient and scalable
data management system specifically developed for hematopoietic
stem cell transplantation of patients with pediatric hematology/
oncology diseases. The data end-users (oncologists and trans-
planters) were critically involved with the system development
and data items incorporated were based on their recommenda-
tions. Ethnic and social characteristics (such as tribal affiliations),
which impact on disease genetics, were also included. The inte-
grated model allows for concentric expansion and linkages that
result in availability of data relating to multiple aspects of each pa-
tient’s care throughout his course, including pre- and post HSCT.
Changes in treatment protocols and diagnostic tests can be easily
incorporated as required. Policies and procedures were developedsimultaneously to direct the workings of this data management
system.
The simplicity, efficiency and scalability of the system design, and
its affordability makes it a model for use in other institutions, espe-
cially in developing countries.93
IMPLEMENTATION OF HEMATOLOGY-ONCOLOGY LECTURE SERIES FOR
HOUSESTAFF
Steinberg, A.S. Cedars-Sinai Medical Center, Los Angeles, CA
Background: We have a ward service dedicated to cancer patients.
Housestaff taking care of these patients includes three interns and
a fellow. There is also a consult service comprising a fellow, an in-
tern, and a resident. There is a need to implement formal, didactic,
teaching devoted to topics in hematology and oncology to improve
quality of care.
Objective: The development of a monthly lecture series for house-
staff rotating on a hematology-oncology rotation focusing on three
key areas:
a) Knowledge tomanage the patients on the hematology-oncology
service
b) What one is most likely to encounter in the practice of medi-
cine, regardless of eventual subspecialty field.
c) Relevance for Internal Medicine exams.
Methods: Topics chosen based on relevance included leukemia,
lymphoma, multiple myeloma, transplantation (these first four
comprising .75% of patients on service), coagulation, breast can-
cer, lung cancer, colon cancer, gynecological cancer, and pain
management/supportive care. Speakers included full-time faculty
as well as private physicians affiliated with the cancer center.
Emails and phone calls were placed to the physicians and an-
nouncements made at division meetings and schedules developed.
Test questions were given to housestaff at the start of their one
month rotation and at the end of rotation. Lectures were sched-
uled for afternoons if possible to avoid conflicts with morning
rounds. Occasional morning talks were necessary however due
to schedule issues. Format of lectures was flexible (power point,
dry-eraser board).
Results:Overall feedback was positive for the lectures. The two con-
ditions affecting optimal success of the program concerned schedul-
ing, including housestaff schedules and availability of when and
which speakers could lecture. The question/answer testing is early
in the process.
Conclusion: A didactic lecture series is an important aspect of stem
cell hematology-oncology education for housestaff and will improve
quality of care of the stem cell transplant service. Repeating lectures
every month is a challenge for several reasons. Possible interventions
in the future may include:
a) Focusing lecturing duties to full-time faculty, with an emphasis
on faculty currently on service
b) Creating power point presentations and handouts on file for use
by multiple people so that rotating faculty may use these materials
for talks
c) Statistical analysis of scores from pre-rotation and post-rotation
exams to assess housestaff performancePHARMACY ORAL
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THE EFFICACY OF APREPITANT ADDED TO ONDANSETRON AND DEXA-
METHASONE FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA
AND VOMITING (CINV) DURING AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT)
Augustin, K.M.1, Hladnik, L.M.1, Dietz, R.2, Gabriel, J.3, Vij, R.3,
Cashen, A.F.3, Stockerl-Goldstein, K.3, Abboud, C.N.3, Nobbe, J.A.1,
Gao, F.4, DiPersio, J.F.3 1Barnes Jewish Hospital, St. Louis, MO;
2Barnes Jewish Hospital, St. Louis, MO; 3Washington University,
St. Louis, MO; 4Washington University, St. Louis, MO
Despite premedication with dexamethasone and ondansetron,
acute and delayed CINV remains a persistent problem in the set-
ting of autologous HSCT. Aprepitant is an oral neurokinin-1
